1350514-68-9 Usage
Description
MK5172, also known as Grazoprevir, is a second-generation NS3/4A protease inhibitor used in the treatment of hepatitis C virus (HCV) infection. It is an azamacrocyclic compound that works by inhibiting the NS3/4A protease enzyme, which is essential for the replication of the virus. MK5172 is often used in combination with the second-generation NS5A inhibitor, Elbasvir (E501010), under the brand name Zepatier, for the treatment of chronic HCV genotypes 1 or 4 infection in adults. Additionally, it is a COVID-19-related research product, indicating its potential use in studying and combating the novel coronavirus.
Uses
Used in Pharmaceutical Industry:
MK5172 is used as an antiviral agent for the treatment of hepatitis C virus infection. It targets the NS3/4A protease enzyme, which is crucial for the replication of the virus, thereby inhibiting its growth and spread within the body.
Used in Combination Therapy:
MK5172 is used in combination with Elbasvir (E501010), a second-generation NS5A inhibitor, to enhance the treatment efficacy for chronic HCV genotypes 1 or 4 infection in adults. This combination therapy helps in achieving a higher rate of sustained virologic response, leading to better patient outcomes.
Used in COVID-19 Research:
MK5172 is used as a research product in the context of COVID-19, where it may contribute to the understanding of the virus and the development of potential treatments or therapies against the novel coronavirus.
Check Digit Verification of cas no
The CAS Registry Mumber 1350514-68-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,0,5,1 and 4 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1350514-68:
(9*1)+(8*3)+(7*5)+(6*0)+(5*5)+(4*1)+(3*4)+(2*6)+(1*8)=129
129 % 10 = 9
So 1350514-68-9 is a valid CAS Registry Number.
1350514-68-9Relevant articles and documents
Synthesis of Grazoprevir, a Potent NS3/4a Protease Inhibitor for the Treatment of Hepatitis C Virus
Xu, Feng,Kim, Jungchul,Waldman, Jacob,Wang, Tao,Devine, Paul
, p. 7261 - 7265 (2018)
An efficient synthesis of grazoprevir is reported. Starting from four readily available building blocks, grazoprevir is prepared in 51% overall yield and >99.9% purity for pharmaceutical use.
Inhibitors of nedd8-activating enzyme
-
Paragraph 0190, (2014/08/20)
The invention relates to an administration unit comprising crystalline form I of {(1 S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216) hydrochloride salt and to a packaging comprising the administration unit according to the invention.
Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors
-
Page/Page column 10, (2010/03/02)
The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.